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Abstract
Background:  Feeding oxidized fats causes activation of peroxisome proliferator-activated
receptor α (PPARα) in the liver of rats. However, whether feeding oxidized fat during pregnancy
also results in activation of PPARα in fetal liver is unknown. Thus, this study aimed to explore
whether feeding oxidized fat during pregnancy causes a PPARα response in fetal liver. Two
experiments with pregnant rats which were administered three different diets (control; oxidized
fat; clofibrate as positive control) in a controlled feeding regimen during either late pregnancy (first
experiment) or whole pregnancy (second experiment) were performed.
Results: In both experiments pregnant rats treated with oxidized fat or clofibrate had higher
relative mRNA concentrations of the PPARα-responsive genes acyl-CoA oxidase (ACO),
cytochrome P450 4A1 (CYP4A1), L-type carnitin-palmitoyl transferase I (L-CPT I), medium-chain
acyl-CoA dehydrogenase (MCAD), and long-chain acyl-CoA dehydrogenase (LCAD) in the liver
than control rats (P < 0.05). In addition, in both experiments fetuses of the oxidized fat group and
the clofibrate group also had markedly higher relative mRNA concentrations of ACO, CYP4A1,
CPT I, MCAD, and LCAD in the liver than those of the control group (P < 0.05), whereas the
relative mRNA concentrations of PPARα, SREBP-1c, and FAS did not differ between treatment
groups. In the second experiment treatment with oxidized fat also reduced triacylglycerol
concentrations in the livers of pregnant rats and fetuses (P < 0.05).
Conclusion: The present study demonstrates for the first time that components of oxidized fat
with PPARα activating potential are able to induce a PPARα response in the liver of fetuses.
Moreover, the present study shows that feeding oxidized fat during whole pregnancy, but not
during late pregnancy, lowers triacylglycerol concentrations in fetal livers.
Background
In recent years the contribution of dietary oxidized fats to
total energy intake has markedly increased in industrial-
ized countries, mainly, due to the increasing consumption
of fast food which contain significant amounts of these
heated and processed fats. We and others have shown that
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oxidized fats are strong activators of peroxisome prolifer-
ator-activated receptor α (PPARα) [1-3], a ligand-acti-
vated transcription factor that belongs to the family of
nuclear receptors. PPARα is centrally involved in the regu-
lation of lipid homeostasis in the liver and is essential for
normal liver function [4]. Upon activation of PPARα by a
ligand, which includes the fibrate class of hypolipidemic
drugs such as clofibrate or fenofibrate, fatty acids, and
eicosanoids, the transcription of genes containing a PPAR
response element (PPRE) in its promoter region is
induced. Typical PPARα-responsive genes in the liver,
which are also up-regulated by oxidized fats and its com-
ponents such as oxidized fatty acids (e.g. hydroperoxy-
fatty acids, cyclic fatty acids) [1-3,5,6], include a wide
array of genes that are involved in peroxisomal and mito-
chondrial fatty acid β-oxidation such as L-type carnitin-
palmitoyl transferase I (L-CPT I), acyl-CoA oxidase
(ACO), cytochrome P450 4A1 (CYP4A1), medium-chain
acyl-CoA dehydrogenase (MCAD), and long-chain acyl-
CoA dehydrogenase (LCAD) [7,8]. PPARα activation by
oxidized fat was also shown to cause liver enlargement
due to peroxisome proliferation and reduce triacylglycerol
concentrations in liver, plasma, and very low-density lipo-
proteins in rats [3,9,10]. In part, the triacylglycerol-lower-
ing effect of oxidized fat in the rat is presumably also due
to the observed reduction in mRNA concentrations and
activities of lipogenic enzymes such as fatty acid synthase
(FAS) [9].
During pregnancy treatment of rats with the pharmaco-
logical PPARα activator clofibrate has been shown to
cause proliferation of peroxisomes [11,12], induction of
peroxisomal enzyme activities [13], and induction of
CYP4A1 in fetal liver [14] indicating that clofibrate is
capable of activating PPARα transplacentally. In addition,
pathological changes in newborn rats born to mothers
treated with clofibrate during pregnancy [15], and an
impaired fetal growth of fenofibrate-treated pregnant rats
have been reported [16]. Moreover, in rat and mouse liver
epithelial cells treatment with the PPARα agonist WY-
14,643 caused up-regulation of proto-oncogenes [17-19],
which has been attributed to the hepatocarcinogenic
effect of peroxisome proliferators in rodents [18]. How-
ever, whether feeding oxidized fat to pregnant rats also
results in activation of PPARα and up-regulation of
PPARα target genes in fetal livers is unknown from the lit-
erature. Moreover, it is unknown whether components of
oxidized fats such as oxidized fatty acids are able to sub-
stantially pass the placenta and enter the fetus, because it
has been shown that the transplacental transport of fatty
acids from the maternal diet is highly selective for individ-
ual fatty acids, e.g. long-chain polyunsaturated fatty acids
such as docosahexaenoic acid and arachidonic acid are
preferentially transported through the placenta at the
expense of other less important fatty acids [20-22].
Therefore, the present study aimed to explore whether
feeding oxidized fat during pregnancy causes a PPARα
response in fetal liver as estimated by the up-regulation of
typical PPARα-responsive genes such as ACO, L-CPT I,
CYP4A1, MCAD, and LCAD and whether the induction of
fatty acid catabolism might also affect fetal hepatic tria-
cylglycerol concentrations. We also analyzed the mRNA
abundance of the lipogenic transcription factor sterol reg-
ulatory-element binding protein (SREBP)-1c and its target
gene FAS, because in previous studies administration of
oxidized fats has also been demonstrated to reduce mRNA
expression of lipogenic enzymes [9]. To address possible
adverse effects of treatment with oxidized fat, we also
determined the mRNA abundance of the proto-oncogenes
c-myc, c-jun, and c-fos.
Since the duration of administration of oxidized fat dur-
ing pregnancy might also influence the effect on lipid
metabolism in the fetal liver, we performed two experi-
ments which varied in the duration of administration of
the oxidized fat. In the first experiment we investigated the
effect of short-term administration (last 5 d of pregnancy)
of oxidized fat on the PPARα response in maternal and
fetal liver, whereas in the second experiment the effect of
long-term administration (whole pregnancy) was studied.
Results
Fatty acid composition and concentrations of lipid 
peroxidation products in the experimental fats
The oxidized fat in the short-term experiment had lower
proportions of polyunsaturated fatty acids (C18:2) but
higher proportions of saturated (C16:0, C18:0) and
monounsaturated (C18:1) fatty acids compared to the
control fat due to the heat treatment of sunflower oil dur-
ing preparation of the oxidized fat (Table 1). In the long-
term experiment the proportions of C18:2 and C18:1 in
the oxidized fat were similar to those in the control fat due
to adjustment of fatty acid composition of the control fat,
whereas the proportions of saturated fatty acids were
lower in the oxidized fat compared to the control fat
(Table 2). In both experiments the oxidized fat had higher
concentrations of peroxides, TBARS, and conjugated
dienes, and a higher acid value than the fat of the control
group. The concentrations of lipid peroxidation products
(peroxide value and conjugated dienes) in the control fat
were higher in the long-term experiment than in the short-
term experiment. This is probably due to the fact that fats
in the long-term experiment were included into a semi-
synthetic diet which contained pro-oxidant minerals such
as iron or copper whereas fats in the short-term experi-
ment were administered the rats directly by gastric tube.Lipids in Health and Disease 2007, 6:6 http://www.lipidworld.com/content/6/1/6
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Final body weights and relative liver weights of pregnant 
rats
Body weight development was not affected by dietary
treatment in both experiments due to the controlled feed-
ing regimen applied. In the short-term experiment, final
body weights of pregnant rats at d 21 of pregnancy did not
differ between the three treatment groups (control, 300 ±
28 g; oxidized fat, 299 ± 24 g; clofibrate, 307 ± 17 g, mean
± SD). Pregnant rats treated with clofibrate or oxidized fat
had higher relative liver weights than control rats (P <
0.05; control, 3.6 ± 0.2 g/100 g body weight; oxidized fat,
4.4 ± 0.3 g/100 g body weight; clofibrate, 4.9 ± 0.2 g/100
g body weight).
In the long-term experiment, final body weights of preg-
nant rats at d 21 of pregnancy were also not different
between treatment groups (control, 342 ± 35 g; oxidized
fat, 331 ± 40 g; clofibrate, 328 ± 18 g). Relative liver
weights of pregnant rats treated with clofibrate or oxidized
fat were also higher than those of control rats (P < 0.05;
control, 3.4 ± 0.2 g/100 g body weight; oxidized fat, 4.4 ±
0.5 g/100 g body weight; clofibrate, 4.5 ± 0.3 g/100 g body
weight).
Relative mRNA concentrations of PPARα and PPARα-
responsive genes in livers of pregnant rats and fetuses
In the short-term experiment, relative mRNA concentra-
tions of PPARα in the liver of pregnant rats and fetuses
were not different between treatment groups (pregnant
rats: 1.00 ± 0.49, control group; 1.02 ± 0.48, oxidized fat
group; 1.26 ± 0.22, clofibrate group; P = 0.439; fetuses:
1.00 ± 0.29, control group; 1.29 ± 0.50, oxidized fat
group; 1.15 ± 0.74, clofibrate group; P = 0.653). Pregnant
rats treated with oxidized fat had 2.4-, 3.0-, 2.5- and 2.1-
fold higher relative mRNA concentrations of ACO,
CYP4A1, MCAD, and LCAD, respectively, in the liver than
control rats (P < 0.05; Fig. 1). The relative mRNA concen-
tration of L-CPT I did not differ between both groups of
rats. Treatment of pregnant rats with clofibrate resulted in
4.8-, 11-, 1.6-, 2.5- and 2.4-fold higher relative mRNA
concentrations of ACO, CYP4A1, L-CPT I, MCAD, and
LCAD, respectively, in the liver compared to control treat-
ment (P < 0.05). Fetuses of the oxidized fat group had 6.3-
Table 2: Characteristics of the experimental fats of the long-term experiment
Treatment group Control Clofibrate Oxidized fat
Fat SFO2 : lard (54:46) oxidized SFO2
Major fatty acids, g/100 g total fatty acids
C16:0 14.9 10.2
C18:0 9.5 6.2
C18:1 (n-9) 28.9 34.4
C18:2 (n-6) 42.0 44.2
Peroxidation products
Peroxide value, mEq O2/kg 6.6 230
Conjugated dienes, mmol/kg 12.3 139
TBARS2, mmol/kg 1.0 19
1Prepared by heating at a temperature of 60°C for 25 d.
2Abbreviations: SFO, sunflower oil; TBARS, thiobarbituric acid-reactive substances.
Table 1: Characteristics of the experimental fats of the short-term experiment
Treatment group Control Clofibrate Oxidized fat1
Fat SFO2 oxidized SFO2
Major fatty acids, g/100 g total fatty acids
C16:0 6.1 9.1
C18:0 3.4 5.3
C18:1 (n-9) 32.6 38.3
C18:2 (n-6) 56.6 44.7
Peroxidation products
Peroxide value, mEq O2/kg 3.0 379
Acid value, g KOH/kg 0.4 5.8
Conjugated dienes, mmol/kg < 0.1 274
TBARS2, mmol/kg 1.1 13.1
1Prepared by heating at a temperature of 60°C for 25 d.
2Abbreviations: SFO, sunflower oil; TBARS, thiobarbituric acid-reactive substances.Lipids in Health and Disease 2007, 6:6 http://www.lipidworld.com/content/6/1/6
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, 9.0-, 6.4-, 1.5- and 2.1-fold higher relative mRNA con-
centrations of ACO, CYP4A1, L-CPT I, MCAD, and LCAD
respectively, in the liver than those of the control group (P
< 0.05), whereas fetuses of the clofibrate group had 20-,
51-, 12-, 2.8- and 3.0-fold higher relative mRNA concen-
tration of ACO, CYP4A1, L-CPT I, MCAD, and LCAD,
respectively in the liver than those of the control group (P
< 0.05).
In the long-term experiment, relative mRNA concentra-
tions of PPARα in the liver of pregnant rats and fetuses
also did not differ between treatment groups (pregnant
rats: 1.00 ± 0.49, control group; 1.56 ± 0.99, oxidized fat
group; 0.63 ± 0.29, clofibrate group; P = 0.053; fetuses:
1.00 ± 0.70, control group; 0.72 ± 0.20, oxidized fat
group; 0.75 ± 0.31, clofibrate group; P = 0.201). Treat-
ment of pregnant rats with oxidized fat resulted in 4.0-,
4.4-, 2.5-, 2.8- and 2.0-fold higher relative mRNA concen-
trations of ACO, CYP4A1, L-CPT I, MCAD, and LCAD,
respectively, in the liver compared to control treatment (P
< 0.05; Fig. 1). Pregnant rats treated with clofibrate had
4.8-, 8.3-, 2.0- and 1.9-fold higher relative mRNA concen-
trations of ACO, CYP4A1, MCAD, and LCAD, respec-
tively, in the liver than control rats (P < 0.05), whereas the
relative mRNA concentration of L-CPT I did not differ
between both treatment groups. Fetuses of the oxidized
fat group had 2.2-, 6.0-, 3.2- and 2.0-fold higher relative
mRNA concentrations of ACO, CYP4A1, MCAD, and
LCAD, respectively, in the liver than those of the control
group (P < 0.05), whereas the relative mRNA concentra-
tion of L-CPT I did not differ between both treatment
groups. Fetuses of the clofibrate group had 3.5-, 28-, 18-
and 3.9-fold higher relative mRNA concentration of ACO,
CYP4A1, L-CPT I, and LCAD, respectively, in the liver than
those of the control group (P < 0.05), whereas the relative
mRNA concentration of MCAD did not differ between
both treatment groups.
Relative mRNA concentrations of SREBP-1c and FAS in 
livers of pregnant rats and fetuses
In the short-term experiment, treatment of pregnant rats
with oxidized fat resulted in lower relative mRNA concen-
trations of FAS in the liver relative to control treatment (P
< 0.05), whereas the relative mRNA concentration of
SREBP-1c did not differ between these two groups (Fig. 2).
Relative mRNA concentrations of SREBP-1c and FAS in
the liver of pregnant rats treated with clofibrate did not
differ from those of control rats. However, pregnant rats
treated with clofibrate had higher relative mRNA concen-
trations of SREBP-1c in the liver than those fed oxidized
fat (P < 0.05). In fetal livers relative mRNA concentrations
of SREBP-1c and FAS did not differ between treatment
groups.
In the long-term experiment, relative mRNA concentra-
tions of SREBP-1c and FAS in the liver of pregnant rats and
fetuses did not differ between the three treatment groups
(Fig. 2).
Concentrations of triacylglycerols in livers of pregnant rats 
and fetuses
In the short-term experiment, concentrations of triacylg-
lycerols in the liver of pregnant rats did not differ between
the three treatment groups (Fig. 3). Fetuses of the clofi-
brate group had lower concentrations of triacylglycerols in
the liver than those of the control and the oxidized fat
group (P < 0.05); oxidized fat had no effect on the triacly-
glycerol concentration in fetal livers compared to control.
In the long-term experiment, treatment of pregnant rats
with oxidized fat or clofibrate resulted in lower concentra-
tions of triacylglycerols in the liver compared to control
treatment (P < 0.05). Fetuses of the oxidized fat group and
the clofibrate group also had lower concentrations of tria-
cylglycerols in the liver than those of the control group (P
< 0.05).
Relative mRNA concentrations of c-myc, c-jun, and c-fos in 
livers of pregnant rats and fetuses
In the short-term experiment, relative mRNA concentra-
tions of c-myc, c-jun, and c-fos in the liver of pregnant rats
and fetuses did not differ between the three treatment
groups (Fig. 4).
In the long-term experiment, treatment of pregnant rats
with oxidized fat resulted in higher relative mRNA con-
centrations of c-myc, c-jun, and c-fos relative to control
treatment (P < 0.05). In fetal livers relative mRNA concen-
trations of c-myc, c-jun, and c-fos did not differ between
treatment groups.
Discussion
The present study demonstrates for the first time that
components of oxidized fat with PPARα activating poten-
tial are able to induce a PPARα response in the liver of
fetuses. Moreover, the present study shows that feeding
oxidized fat during whole pregnancy, but not during late
pregnancy, lowers triacylglycerol concentrations in fetal
livers. Hydroxy- and hydroperoxy-fatty acids such as
hydroxyoctadecadienoic acid (HODE) and hydroperoxy-
octadecadienoic acid (HPODE) occurring in oxidized fats
are very potent PPARα agonists [6,23,24]. These oxidized
fatty acids are produced during the early stage of lipid per-
oxidation, and, due to their low thermodynamic stability,
easily decompose at high temperatures. Thus, fats treated
at low temperatures have markedly higher concentrations
of these primary lipid peroxidation products than fats
treated at high temperature [3]. Therefore, in order to pro-
voke a significant PPARα activating effect of the oxidizedLipids in Health and Disease 2007, 6:6 http://www.lipidworld.com/content/6/1/6
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Effects of treatment on relative mRNA concentrations of PPARα-responsive genes in livers of pregnant rats and fetuses Figure 1
Effects of treatment on relative mRNA concentrations of PPARα-responsive genes in livers of pregnant rats 
and fetuses. Effect of short-term (d 16 – d 21 of pregnancy, left) and long-term (d 1 – d 21 of pregnancy, right) administration 
of three different diets (control, oxidized fat, clofibrate) during pregnancy on relative mRNA concentrations of ACO, CYP4A1, 
CPT I, MCAD, and LCAD in the liver of pregnant rats and fetuses at d 21 of pregnancy. Left, Bars represent mean ± SD (n = 9/
group). Right, Bars represent mean ± SD (n = 12/group). Bars marked without a common superscript letter differ (P < 0.05). 
Results from one-way ANOVA (P-values): short-term experiment: ACO, P = 0.0001 (pregnant), P = 0.001 (fetus); CYP4A1, P 
= 0.0001 (pregnant), P = 0.002 (fetus); L-CPT I, P = 0.013 (pregnant), P = 0.012 (fetus); MCAD, P = 0.042 (pregnant), P = 0.001 
(fetus); LCAD, P = 0.001 (pregnant), P = 0.03 (fetus); long-term experiment: ACO, P = 0.0001 (pregnant), P = 0.015 (fetus); 
CYP4A1, P = 0.0001 (pregnant), P = 0.001 (fetus); L-CPT I, P = 0.016 (pregnant), P = 0.011 (fetus); MCAD, P = 0.001 (preg-
nant), P = 0.019 (fetus); LCAD, P = 0.001 (pregnant), P = 0.001 (fetus).
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fat, we decided to use a fat treated at a relatively low tem-
perature for a long period. Although we did not determine
the concentrations of oxidized fatty acids such as 13-
HODE or 13-HPODE in the oxidized fat, the high perox-
ide value and the high concentration of conjugated dienes
indicate that the oxidized fats used in both experiments
presumably had high concentrations of hydroxy- and
hydroperoxy-fatty acids which may be particularly
responsible for the PPARα activating effect of oxidized
fats. Nonetheless, other components of heated fats such as
cyclic fatty acid monomers which also show a strong
PPARα response [5] might be also causative for PPARα
activation.
The lower concentrations of primary lipid peroxidation
products (peroxides, conjugated dienes) in the oxidized
fat used in the long-term experiment compared to that
used in the short-term experiment are probably explained
by the fact that in the long-term experiment the lipid per-
oxidation products in the oxidized fat were determined
after inclusion into the diet. Primary lipid peroxidation
products easily decompose and are partially degraded in
the presence of other diet components such as metal ions
(e.g. iron, copper) acting as catalysts.
Since unspecific effects might have been caused by a dif-
ferent fatty acid composition of the experimental fats (the
heating process caused a loss of polyunsaturated fatty
acids), we aimed at equalizing in particular the concentra-
tion of the polyunsaturated fatty acid C18:2 (n-6) in the
fresh fat and the oxidized fat in the second experiment
which lasted during the whole pregnancy. Although the
Effects of treatment on relative mRNA concentrations of SREBP-1c and FAS in livers of pregnant rats and fetuses Figure 2
Effects of treatment on relative mRNA concentrations of SREBP-1c and FAS in livers of pregnant rats and 
fetuses. Effect of short-term (d 16 – d 21 of pregnancy, left) and long-term (d 1 – d 21 of pregnancy, right) administration of 
three different diets (control, oxidized fat, clofibrate) during pregnancy on relative mRNA concentrations of SREBP-1c and FAS 
in the liver of pregnant rats and fetuses at d 21 of pregnancy. Left, Bars represent mean ± SD (n = 9/group). Right, Bars repre-
sent mean ± SD (n = 12/group). Bars marked without a common superscript letter differ (P < 0.05). Results from one-way 
ANOVA (P-values): short-term experiment: SREBP-1c, P = 0.041 (pregnant), P = 0.058 (fetus); FAS, P = 0.026 (pregnant), P = 
0.425 (fetus); long-term experiment: SREBP-1c, P = 0.526 (pregnant), P = 0.189 (fetus); FAS, P = 0.716 (pregnant), P = 0.334 
(fetus).
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concentrations of the long-chain saturated fatty acids
C16:0 and C18:0 were consequently decreased in the oxi-
dized fat compared to the fresh fat, we think that these dif-
ferences are not responsible for the differences in the
PPARα response observed between the experimental
groups, because saturated long chain-fatty acids were
shown to bind and activate PPARα only very weakly com-
pared to polyunsaturated fatty acids such as C18:2 (n-6)
[25]. Therefore, we assume that the PPARα response to an
oxidized fat might depend on the balance between unox-
idized fatty acids with low PPARα transactivation activity
and oxidized fatty acids with high PPARα transactivation
activity because both types of fatty acids compete for the
PPARα-ligand binding site.
A further consequence of the use of lard in the control fat
was that the cholesterol content of the control and the
clofibrate diet slightly differed from that of the oxidized
fat diet. However, based on an average cholesterol con-
centration of about 80 mg per 100 g lard the control and
the clofibrate diet contained less than 0.004% cholesterol.
Therefore, we assume that the slight difference in the cho-
lesterol concentration between the experimental diets is
negligible, especially since no relation between PPARα
activation and dietary cholesterol is known from the liter-
ature.
The present study clearly shows that feeding oxidized fat
during pregnancy, similar to clofibrate, which was used as
a positive control, causes not only a PPARα response in
the liver of pregnant animals as shown by liver enlarge-
ment and up-regulation of PPARα-responsive genes but
also in the liver of the fetuses. Although the induction of
the PPARα response by oxidized fat in the fetal liver was
not as pronounced as observed with clofibrate, the oxi-
dized fat also caused a strong up-regulation of PPARα-tar-
get genes of up to 9-fold in the livers of fetuses which was
even more pronounced than the effect of oxidized fat in
the livers of pregnant rats. Therefore, these findings sug-
gest that not only pharmacological PPARα activators but
also components of oxidized fat are able to sufficiently
pass the placenta and activate PPARα in the fetal liver.
This finding is novel since the placental transfer of these
components of oxidized fat with PPARα activating poten-
tial from the maternal diet to the fetus is unknown.
Indeed, the transplacental transport of fatty acids is highly
selective for individual fatty acids [20-22], but no data are
available from the literature with respect to the placental
passage of oxidized fatty acids which are presumably deci-
sive for the PPARα activating effect of oxidized fat. Thus,
the present results indicate that these critical components
of oxidized fats are also sufficiently transported across the
placenta. Moreover, the observation from the short-term
experiment that up-regulation of mRNA expression of
ACO, CYP4A1 and L-CPT I by oxidized fat in the fetal liver
was even more pronounced than in the liver of pregnant
rats indicates that components of oxidized fat responsible
for PPARα activation are presumably transported through
the placenta with high preference.
Effects of treatment on triacylglycerol concentrations in livers of pregnant rats and fetuses Figure 3
Effects of treatment on triacylglycerol concentrations in livers of pregnant rats and fetuses. Effect of short-term 
(d 16 – d 21 of pregnancy, left) and long-term (d 1 – d 21 of pregnancy, right) administration of three different diets (control, 
oxidized fat, clofibrate) during pregnancy on triacylglycerol concentrations in the liver of pregnant rats and fetuses at d 21 of 
pregnancy. Left, Bars represent mean ± SD (n = 9/group). Right, Bars represent mean ± SD (n = 12/group). Bars marked with-
out a common superscript letter differ (P < 0.05). Results from one-way ANOVA (P-values): short-term experiment: P = 0.239 
(pregnant), P = 0.025 (fetus); long-term experiment: P = 0.0001 (pregnant), P = 0.045 (fetus).
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Effects of treatment on relative mRNA concentrations of proto-oncogenes in livers of pregnant rats and fetuses Figure 4
Effects of treatment on relative mRNA concentrations of proto-oncogenes in livers of pregnant rats and 
fetuses. Effect of short-term (d 16 – d 21 of pregnancy, left) and long-term (d 1 – d 21 of pregnancy, right) administration of 
three different diets (control, oxidized fat, clofibrate) during pregnancy on relative mRNA concentrations of c-myc, c-jun, and 
c-fos in the liver of pregnant rats and fetuses at d 21 of pregnancy. Left, Bars represent mean ± SD (n = 9/group). Right, Bars 
represent mean ± SD (n = 12/group). Bars marked without a common superscript letter differ (P < 0.05). Results from one-
way ANOVA (P-values): short-term experiment: c-myc, P = 0.880 (pregnant), P = 0.807 (fetus); c-jun, P = 0.362 (pregnant), P = 
0.552 (fetus); c-fos, P = 0.669 (pregnant), P = 0.966 (fetus); long-term experiment: c-myc, P = 0.001 (pregnant), P = 0.420 
(fetus); c-jun, P = 0.0001 (pregnant), P = 0.086 (fetus); c-fos, P = 0.048 (pregnant), P = 0.323 (fetus).
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Since activation of hepatic PPARα by clofibrate or oxi-
dized fat has been demonstrated to enhance the fatty acid
oxidation capacity in the liver and to lower hepatic tria-
cylglycerol concentrations in non-pregnant rats [1,3,9],
we also studied the effect of oxidized fat on the concentra-
tions of triacylglycerols in the fetal liver. Indeed, we could
demonstrate that feeding the oxidized fat during preg-
nancy also reduced the concentrations of triacylglycerols
in the fetal liver indicating that the transplacental induc-
tion of PPARα responsive genes enhanced the peroxiso-
mal and mitochondrial fatty acid oxidation capacity of the
fetal liver. However, this effect has only been observed
when the oxidized fat was fed during the whole preg-
nancy, but not when the oxidized fat was fed for the last 5
d of pregnancy only, although the PPARα responsive
genes were markedly up-regulated in fetal livers of preg-
nant rats treated during either whole or late pregnancy.
This suggests that short-term administration of oxidized
fat to pregnant rats causes significant alterations on the
gene expression level, which have no implications on the
phenotypic level, e.g. triaclyglycerol concentrations. In
contrast, short-term administration of clofibrate during
pregnancy even revealed alterations on the phenotypic
level as evidenced by reduced triacylglycerol concentra-
tions in fetal livers. The latter might be attributed to the
fact that clofibrate caused a more pronounced activation
of PPARα in fetal livers due to a higher affinity for PPARα
compared to oxidized fat leading to a marked induction of
fatty acid oxidation and a significant lowering of triacylg-
lycerol concentrations in fetal livers even after short-term
exposure to clofibrate.
Interestingly, no effect of oxidized fat and even clofibrate
on hepatic triacylglycerol concentrations following short-
term treatment could be observed in pregnant rats,
although clofibrate reduced triacylglycerol concentrations
in fetal livers following short-term treatment. The failure
of clofibrate or oxidized fat to reduce hepatic triacylglyc-
erol concentrations in pregnant rats in the short-term
experiment might be attributed to the fact that treatment
was only performed during late pregnancy when signifi-
cant alterations in lipid metabolism [e.g. hypertriacylglyc-
erolemia as a consequence of enhanced adipose tissue
lipolytic activity, enhanced liver production of VLDL par-
ticles, and decreased extrahepatic lipoprotein lipase activ-
ity [26-29]] occur in the pregnant animal. The enhanced
arrival of free fatty acids, which also serve as ligands for
PPARα, in the liver during late pregnancy could decrease
the availability for the stronger PPARα activators clofi-
brate or components of oxidized fat with PPARα activat-
ing potential to their PPARα-ligand binding site. This in
turn could reduce the capability of fibrates or oxidized fat
to activate PPARα and consequently, its metabolic effects.
This might be important since a substantial body of evi-
dence suggests that not all alterations in gene transcrip-
tion induced by pharmacological PPARα activators are
also induced by fatty acids [30], e.g. some genes that con-
tain a PPRE do not respond to fatty acids but to high-affin-
ity PPARα activators [31-33]. Thus, administration of
oxidized fat or clofibrate during late pregnancy might pro-
voke differential effects on lipid metabolism than in vir-
gin or early pregnant rats. The observation that treatment
of rats with the triacylglycerol-lowering PPARα agonist
fenofibrate during late pregnancy even increased triacylg-
lycerol concentrations in plasma, whereas in virgin rats
treatment with fenofibrate caused a reduction in plasma
triacylglycerol concentrations [16], is probably supportive
of this assumption.
Whether the effect observed with oxidized fat or clofibrate
might have been also influenced by the metabolic state,
e.g. fasting vs. non-fasting, cannot be answered with cer-
tainty. In the present study we decided to perform gene
expression analysis of PPARα-responsive genes in the liver
in the non-fasting state, because lipolysis of stored tria-
cylglycerols in adipose tissue is strongly activated during
fasting, resulting in a marked increase in plasma free fatty
acid levels. These free fatty acids act as endogenous PPARα
ligands and might have competed with the exogenous lig-
ands (e.g. clofibrate, oxidized fatty acids or cyclic fatty acid
monomers) for the PPARα-ligand binding site. Therefore,
an altered ratio between endogenous free fatty acids and
exogenous oxidized fatty acids as a consequence of the
fasting state might have provoked a different PPARα
response in the liver of pregnant rats and fetuses than
observed in the non-fasting state. However, further studies
are required to definitely resolve this question.
Only slight effects have been observed in the present study
with respect to the lipogenic transcription factor SREBP-1c
and its target gene FAS. Namely, oxidized fat caused a
slight reduction in the mRNA abundance of FAS in the
liver of pregnant rats, which is consistent with recent find-
ings in non-pregnant rats [9]. However, no effect of oxi-
dized fat has been observed on gene expression of
lipogenic enzymes in fetal livers indicating that the
reduced hepatic triacylglycerol concentrations in fetuses
from pregnant rats treated with oxidized fat are probably
largely due to an enhanced fatty acid oxidation capacity
due to transplacental activation of PPARα. In part, the fail-
ure of oxidized fat on FAS gene expression in fetal livers
might be explained by the fact that lipogenesis in fetal liv-
ers is generally very low and only increased during late
pregnancy [34], and, therefore, probably does not
respond to variations in the maternal diet.
Since pathological changes in newborn rats born to moth-
ers treated with clofibrate during pregnancy have been
reported [15], treatment with fenofibrate has been shown
to impair fetal growth [16], and a link between inducedLipids in Health and Disease 2007, 6:6 http://www.lipidworld.com/content/6/1/6
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CYP4A1 expression, peroxisome proliferation, and car-
cinogenesis in rat livers has been described [35], we also
addressed possible adverse effects of treatment with oxi-
dized fat on fetal livers. With respect to the hepatocarcino-
genic effect of peroxisome proliferators in rodents it has
been suggested that enhanced DNA synthesis as a conse-
quence of up-regulation of proto-oncogenes including c-
fos, c-jun, and c-myc might be mechanistically involved
[17-19]. In the present study an up-regulation of proto-
oncogenes in the livers of pregnant rats has been observed
in the long-term experiment, but not in the short-term
experiment, indicating that short-term administration of
oxidized fat has no impact on mRNA expression of proto-
oncogenes. However, in fetal livers mRNA expression of
proto-oncogenes was not affected by oxidized fat regard-
less of the duration of oxidized fat administration suggest-
ing that the oxidized fat is uncritical with respect to
hepatocarcinogenesis. Unexpectedly, treatment with clof-
ibrate had no effect on proto-oncogene expression in
pregnant rats and fetuses either in the short-term and the
long-term experiment, although it has been reported that
the high-affinity PPARα-ligand WY-14,643 strongly up-
regulated various proto-oncogenes in rat and mouse liver
epithelial cells [18,19]. This differential action of WY-
14,643 and clofibrate on proto-oncogene mRNA expres-
sion cannot be explained at the moment and, therefore,
requires further research activities.
Although oxidized fat had no effect on proto-oncogene
expression in fetal livers in the present study, oxidized fats
might be considered critically in view of inducing oxida-
tive stress in different tissues as shown in recent studies
[36,37]. In addition, specific components of oxidized fats
such as cyclic fatty acid monomers, which are formed in
substantial amounts during domestic frying of frozen
foods in sunflower oil [38], are probably toxic, e.g. earlier
studies reported that mice receiving cyclic fatty acid mon-
omers as well as rat pups from mothers fed cyclic fatty acid
monomers had a higher death rate [39-41].
Conclusion
In conclusion, the present study demonstrates for the first
time that components of oxidized fat with PPARα activat-
ing potential contained in the maternal diet are able to
induce a PPARα response in the liver of fetuses as evi-
denced by an up-regulation of PPARα target genes. In
addition, the present study shows that feeding oxidized
fat during whole pregnancy, but not during late preg-
nancy, lowers triacylglycerol concentrations in fetal livers,
probably as a consequence of an enhanced peroxisomal
and mitochondrial β-oxidation capacity. Although
administration of oxidized fat during pregnancy had not
impact on fetal proto-oncogene mRNA expression either
after short-term or long-term administration, the
observed pronounced transplacental PPARα activation by
oxidized fat might be considered critically because of
other recently reported adverse effects of treatment with
PPARα activators during pregnancy [15,16]. Therefore,
further research should be encouraged with respect to pos-
sible detrimental effects of oxidized fat on fetal develop-
ment.
Methods
Animals
Two experiments were carried out with female Sprague-
Dawley rats obtained from Charles River (Sulzfeld, Ger-
many). At 11 wk of age, the rats were mated by housing
one male rat with two female rats. D 1 of pregnancy was
assigned upon observation of sperm in the vaginal
smears, at which time rats were randomly assigned to the
treatment groups. The short-term experiment was per-
formed from d 16 to d 21 of pregnancy and included 27
pregnant rats with an initial body weight (d 16 of preg-
nancy) of 297 ± 26 (Mean ± SD) g, which were allotted to
three groups of nine rats each. The long-term experiment
was performed from d 1 to d 21 of pregnancy and
included 36 rats with an initial body weight (d 1 of preg-
nancy) of 238 ± 27 g, which were allotted to three groups
of twelve rats each. Pregnant rats were kept individually in
Macrolon cages in a room maintained with controlled
temperature (23 ± 1°C), humidity (50–60%), and light-
ing (0600 to 1800 h). All experimental procedures
described followed established guidelines for the care and
handling of laboratory animals [42] and were approved
by the council of Saxony-Anhalt.
Diets
Short-term experiment
In the short-term experiment, rats received 2 mL of differ-
ent experimental fats by gavage daily at 0800 h, and, addi-
tionally, fed a commercial standard rodent diet
(Altromin, Lage, Germany). To standardize food intake,
the diets were fed daily in controlled amounts of 16 g per
d. The first group (control group) received sunflower oil,
the second group (oxidized fat group) oxidized fat (see
"preparation of the oxidized fat"), and the third group
(clofibrate group) sunflower oil containing 75 mg clofi-
brate (Fluka, Buchs, Switzerland) equivalent to 250 mg
clofibrate per kg body weight. The experimental fats were
given for 5 d from d 16 of pregnancy to d 21 of pregnancy.
The standard diet was completely consumed by all the
rats. Thus, all the rats within this experiment consumed
identical amounts of the food.
Long-term experiment
In the long-term experiment, semipurified diets, com-
posed according to the recommendations of ASNS for rats
during reproduction [43], were used. The diet consisted of
(g/kg diet): casein, 200; cornstarch, 390; saccharose, 198;
cellulose, 50; fat, 100; mineral mixture, 40; vitamin mix-Lipids in Health and Disease 2007, 6:6 http://www.lipidworld.com/content/6/1/6
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ture, 20; DL-methionine, 2. The type of fat was varied
according to a one-factorial design. The first group (con-
trol group) received a mixture of sunflower oil and lard
(54:46, w/w) was used. This ratio was chosen to equalize
the fatty acid composition of the fresh fat with that of the
oxidized fat, since the heating process caused a loss of pol-
yunsaturated fatty acids, therefore, excluding that the
treatment effects were caused by a different fatty acid com-
position of the experimental fats. The second group (oxi-
dized fat group) received oxidized fat (see "preparation of
the oxidized fat"). The third group (clofibrate group)
received the same fat as in the control group, and clofi-
brate was added to the diet at a concentration of 5 g/kg.
The vitamin E concentration of the diets was 50 mg α-
tocopherol equivalents per kg diet. To adjust the vitamin
E concentration of the diets, the native concentrations of
tocopherols of the fats were analyzed. Based on the native
concentrations of the fats, diets were supplemented indi-
vidually with all-rac-α-tocopheryl acetate (the biopotency
of all-rac-α-tocopheryl acetate is considered to be 67% of
that of α-tocopherol). Diets were prepared by mixing the
dry components with the fat and water and subsequent
freeze drying. The residual water content of the diet was
below 5 g/100 g of diet. In preliminary experiments rats
fed diets with clofibrate or oxidized fat ad libitum con-
sumed their diets over a longer period than rats fed con-
trol diets, which consequently shortened the fasting
period and which itself has a pronounced effect on
PPARα-response. Therefore, we decided to administer
food daily at 0800 h in controlled amounts to standardize
intake and to ensure that rats from all treatment groups
had a comparable fasting period. The amount of food
administered was 20% less than the amounts of identical
diets with fresh fats consumed ad libitum by rats in pre-
liminary studies. The amount of food offered daily was
increased continuously during the experiment from 14 g
to 17 g. In this feeding system, the food offered was com-
pletely consumed by all the rats. Thus, all the rats within
this experiment consumed identical amounts of food. The
experimental diets were fed from d 1 of pregnancy to d 21
of pregnancy.
In both experiments, water was available ad libitum from
nipple drinkers during the whole experiment.
Preparation of the oxidized fat
The oxidized fat was prepared by heating sunflower oil at
a temperature of 60°C for 25 d. Sunflower oil was filled
into a glass beaker and placed into a drying oven set at the
intended temperature. Throughout the heating process,
air was continuously bubbled through the fat at a flow
rate of 650 ml/min. This treatment caused a loss of poly-
unsaturated fatty acids, and a complete loss of tocophe-
rols and raised the concentrations of lipid peroxidation
products in the fats. The extent of lipid peroxidation in the
oxidized fat was estimated by assaying the peroxide value
(POV) [44], acid value [44], concentration of thiobarbitu-
ric acid substances (TBARS) [45], and concentration of
conjugated dienes [46]. To assess lipid peroxidation prod-
ucts in the oxidized fat after inclusion into the diet (long-
term experiment), the fat was extracted from aliquots of
the diets with a mixture of hexane and isopropanol (3:2,
v/v) and analysed for peroxide value, concentration of
conjugated dienes, and TBARS.
Sample collection
4 h after the final portion had been administered the rats
were anesthetized with diethyl ether and killed by decap-
itation. The liver and fetuses were excised immediately,
and frozen with liquid nitrogen. In addition, livers from
three randomly taken fetuses per pregnant rat were
excised, and frozen with liquid nitrogen. All samples were
stored at -80°C pending analysis.
Lipid analysis
Lipids of maternal livers and pools of fetal livers were
extracted with a mixture of hexane and isopropanol (3:2,
v/v) [47]. Total cholesterol and triacylglycerol concentra-
tions were determined using enzymatic reagent kits
obtained from Merck Eurolab (Darmstadt, Germany).
Prior to enzymatic measurement, lipids of the extract were
dissolved in Triton X-100 as described by De Hoff et al.
[48]. Fatty acid composition of experimental fats was
determined by GC-FID analysis of fatty acid methyl esters
(FAME) as described previously in detail [49].
RNA isolation and real-time RT-PCR
For the determination of mRNA expression levels of
PPARα, CYP4A1, ACO, L-CPT I, MCAD, LCAD, SREBP-1c,
FAS, c-myc, c-jun, and c-fos total RNA were isolated from
maternal liver and fetal liver pools using Trizol™ reagent
(Invitrogen, Karlsruhe, Germany) according to the manu-
facturer's protocol. RNA concentration and purity were
estimated from the optical density at 260 and 280 nm,
respectively. cDNA synthesis and relative quantification
of target gene mRNA compared to the housekeeping gene
GAPDH mRNA was determined by real-time detection
RT-PCR as described previously [50]. Sequences of gene-
specific primers obtained from Operon (Köln, Germany)
were as follows (NCBI GenBank; forward, reverse):
GAPDH (NM_017008; 5'-GCA TGG CCT TCC GTG TTC
C-3', 5'-GGG TGG TCC AGG GTT TCT TAC TC-3'), PPARα
(NM_013196; 5'-CCC TCT CTC CAG CTT CCA GCC C-3',
5'-CCA CAA GCG TCT TCT CAG CCA TG-3'), CYP4A1
(M14972; 5'-CAG AAT GGA GAA TGG GGA CAG C-3', 5'-
TGA GAA GGG CAG GAA TGA GTG G-3'), ACO (J02752;
5'-CTT TCT TGC TTG CCT TCC TTC TCC-3', 5'-GCC GTT
TCA CCG CCT CGT A-3'), L-CPT I (NM_031559; 5'-GGA
GAC AGA CAC CAT CCA ACA TA-3', 5'-AGG TGA TGG
ACT TGT CAA ACC-3'), MCAD (NM_016986; 5'-CAALipids in Health and Disease 2007, 6:6 http://www.lipidworld.com/content/6/1/6
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GAG AGC CTG GGA ACT TG-3', 5'-CCC CAA AGA ATT
TGC TTC AA-3'), LCAD (NM_012819; 5'-AAG GAT TTA
AGG GCA AGA AGC-3', 5'-GGA AGC GGA GGC GGA
GTC-3'), SREBP-1c (XM_213329; 5'-GGA GCC ATG GAT
TGC ACA TT-3', 5'-AGG AAG GCT TCC AGA GAG GA-3'),
FAS (NM_017332; 5'-AGG TGC TAG AGG CCC TGC TA-
3', 5'-GTG CAC AGA CAC CTT CCC AT-3'), c-myc
(NM_012603; 5'-CTG GAG TGA GAA GGG CTT TG-3', 5'-
CAG CAG CTC GAA TTT CTT CC-3'), c-jun (NM_021835;
5'-ACC AAG AAT TCC GTG ACG AC-3', 5'-CAA GGT CAT
GCT CTG CTT CA-3'), and c-fos (NM_022197; 5'-CAT
CGG CAG AAG GGG CAA AGT AGA G-3', 5'-TGC CGG
AAA CAA GAA GTC ATC AAA G-3').
Statistical analysis
Treatment effects were analyzed using one-way ANOVA.
For significant F-values, means were compared by Fisher's
multiple range test. Differences with P < 0.05 were consid-
ered significant.
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